Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study

被引:16
|
作者
Tomita, Satoshi [1 ,2 ,3 ]
Oeda, Tomoko [1 ,2 ,3 ]
Umemura, Atsushi [1 ,2 ,3 ]
Kohsaka, Masayuki [1 ,2 ,3 ]
Park, Kwiyoung [1 ,2 ,3 ]
Yamamoto, Kenji [1 ,2 ,3 ]
Sugiyama, Hiroshi [2 ,3 ]
Mori, Chiaki [4 ]
Inoue, Kimiko [4 ]
Fujimura, Harutoshi [4 ]
Sawada, Hideyuki [1 ,2 ,3 ]
机构
[1] Natl Reg Ctr Neurol Disorders, Clin Res Ctr, Kyoto, Japan
[2] Natl Utano Hosp, Kyoto, Japan
[3] Natl Reg Ctr Neurol Disorders, Dept Neurol, Kyoto, Japan
[4] Toneyama Natl Hosp, Dept Neurol, Osaka, Japan
来源
PLOS ONE | 2015年 / 10卷 / 08期
关键词
RICHARDSON-OLSZEWSKI-SYNDROME; MULTIPLE SYSTEM ATROPHY; NATURAL-HISTORY; PARKINSONS-DISEASE; SWALLOWING FUNCTION; DYSPHAGIA; PREDICTORS; SURVIVAL; GAIT; RESPONSIVENESS;
D O I
10.1371/journal.pone.0135823
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction Although aspiration pneumonia is the most common complication of progressive supranuclear palsy (PSP), the clinical impact of aspiration pneumonia on disease course and survival has not been fully estimated. Thus, we retrospectively analyzed the prognostic factors and clinical consequences of pneumonia in PSP. Methods The clinical course of patients with aspiration pneumonia was surveyed. The association between baseline clinical features (2 years from disease onset) and latency to the initial development of pneumonia was investigated using survival time and Cox regression analyses. Results Ninety patients with a clinical diagnosis of PSP were observed for 5.1 +/- 3.8 years (mean +/- SD), and 22 had aspiration pneumonia. Subsequently, 20 patients (91%) had to discontinue oral feeding entirely and 13 (59%) died, whereas, of 68 patients without pneumonia, only three patients (4%) died. Time to initial development of pneumonia was strongly correlated with survival time (Spearman R = 0.92, P<0.001), with a mean latency of 2.3 years to death. Among baseline clinical features, early fall episodes and cognitive decline were significant predictors of pneumonia (P = 0.001 and P<0.001, respectively, log rank test). Cox regression analysis demonstrated that early fall episodes (adjusted hazard ratio: 3.9, 95% confidence interval: 1.2-12.5, P = 0.03) and cognitive decline (adjusted hazard ratio: 5.2, 95% confidence interval: 1.4-19.3, P = 0.02) independently predicted pneumonia. By contrast, dysphagia was not associated with pneumonia (P = 0.2, log rank test). Conclusion Initial development of pneumonia indicates an unfavorable clinical course and predicts survival time (mean survival time 2.3 years). Patients with early falls and cognitive decline were at high risk of early development of pneumonia.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] PROGRESSIVE SUPRANUCLEAR PALSY: A CASE STUDY
    Foley, Mary J.
    O'Connor, Kieran
    Fitzgerald, Eavan
    [J]. AGE AND AGEING, 2016, 45 : 53 - 53
  • [32] Retrospective Review of Amantadine Use in Progressive Supranuclear Palsy
    McFarland, Nikolaus
    Farrukh, Ramsha
    Mahn, Savanna
    [J]. NEUROLOGY, 2023, 100 (17)
  • [33] Accuracy of clinical diagnosis of progressive supranuclear palsy
    Osaki, Y
    Ben-Shlomo, Y
    Lees, AJ
    Daniel, SE
    Colosimo, C
    Wenning, GK
    Quinn, N
    [J]. MOVEMENT DISORDERS, 2004, 19 (02) : 181 - 189
  • [34] STUDY OF SLEEP IN PROGRESSIVE SUPRANUCLEAR PALSY
    PERRET, JL
    JOUVET, M
    [J]. ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1980, 49 (3-4): : 323 - 329
  • [35] The Progressive Supranuclear Palsy Clinical Deficits Scale
    Piot, Ines
    Schweyer, Kerstin
    Respondek, Gesine
    Stamelou, Maria
    Gasser, Thomas
    Hermann, Andreas
    Hoeglinger, Gunter
    Hoellerhage, Matthias
    Kimmich, Okka
    Klockgether, Thomas
    Levin, Johannes
    Machetanz, Gerrit
    Osterrath, Antje
    Palleis, Carla
    Prudlo, Johannes
    Spottke, Annika
    Berg, Daniela
    Buerk, Katrin
    Classen, Joseph
    Eggers, Carsten
    Greuel, Andrea
    Grimm, Max-Joseph
    Hermann, Lennard
    Iankova, Vassilena
    Jahn, Klaus
    Jost, Wolfgang
    Klietz, Martin
    Kuehn, Andrea
    Marxreiter, Franz
    Paschen, Steffen
    Poetter-Nerger, Monika
    Preisl, Marie-Therese
    Prilop, Lisa
    Toenges, Lars
    Trenkwalder, Claudia
    Warnecke, Tobias
    Wegner, Florian
    Winkler, Juergen
    Antonini, Angelo
    Bhatia, Kailash P.
    Boxer, Adam L.
    Colosimo, Carlo
    Compta, Yaroslau
    Corvol, Jean-Christophe
    Golbe, Lawrence I.
    Hoglinger, Guenter U.
    Lang, Anthony E.
    Litvan, Irene
    Morris, Huw R.
    Nilsson, Christer
    [J]. MOVEMENT DISORDERS, 2020, 35 (04) : 650 - 661
  • [36] PROGRESSIVE SUPRANUCLEAR PALSY - CLINICAL AND PATHOLOGICAL DIAGNOSIS
    TOLOSA, E
    VALLDEORIOLA, F
    CRUZSANCHEZ, F
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 1995, 2 (04) : 259 - 273
  • [38] The Progressive Supranuclear Palsy Clinical Deficits Scale
    Respondek, G.
    Piot, I.
    Schweyer, K.
    Stamelou, M.
    Sckopke, P.
    Schenk, T.
    Goetz, C.
    Stebbins, T.
    Hoeglinger, G.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S509 - S510
  • [39] Predictors of survival in Progressive Supranuclear Palsy in a Tunisian cohort
    Neji, A.
    Nasri, A.
    Sghaier, I.
    Mrabet, S.
    BenDjebara, M.
    Kacem, I.
    Gouider, R.
    [J]. MOVEMENT DISORDERS, 2021, 36 : S252 - S253
  • [40] Clinical genetics of familial progressive supranuclear palsy
    Rojo, A
    Pernaute, RS
    Fontán, A
    Ruíz, PG
    Honnorat, J
    Lynch, T
    Chin, S
    Gonzalo, I
    Rábano, A
    Martínez, A
    Daniel, S
    Pramstaller, P
    Morris, H
    Wood, N
    Lees, A
    Tabernero, C
    Nyggard, T
    Jackson, AC
    Hanson, A
    de Yébenes, JG
    [J]. BRAIN, 2000, 123 : 419 - 419